Black Diamond Therapeutics (NASDAQ:BDTX) Given Buy Rating at HC Wainwright

Black Diamond Therapeutics (NASDAQ:BDTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 127.98% from the company’s previous close.

A number of other equities research analysts have also weighed in on BDTX. Raymond James started coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, July 3rd. Finally, Wedbush restated an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a research report on Tuesday, September 10th.

Black Diamond Therapeutics Trading Down 11.0 %

NASDAQ:BDTX opened at $4.83 on Wednesday. Black Diamond Therapeutics has a 12-month low of $1.62 and a 12-month high of $7.66. The stock’s 50 day simple moving average is $5.73 and its 200-day simple moving average is $5.35. The firm has a market cap of $271.42 million, a P/E ratio of -2.91 and a beta of 2.49.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts forecast that Black Diamond Therapeutics will post -1.4 EPS for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

Large investors have recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Black Diamond Therapeutics in the 1st quarter worth about $82,000. Foundations Investment Advisors LLC grew its position in shares of Black Diamond Therapeutics by 17.7% in the second quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company’s stock valued at $529,000 after purchasing an additional 17,050 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Black Diamond Therapeutics by 13.8% during the 1st quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after purchasing an additional 20,616 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Black Diamond Therapeutics in the 2nd quarter valued at approximately $108,000. Finally, Jump Financial LLC grew its holdings in Black Diamond Therapeutics by 245.0% during the 4th quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock valued at $109,000 after buying an additional 27,616 shares during the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.